NeurAxis, Inc. NRXS · Stock Open NeurAxis, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
NeurAxis, Inc. Analysis (NRXS)
Is NeurAxis, Inc. a good investment? NeurAxis, Inc. (NRXS) is currently trading at 7.44 USD. Market analysts have a consensus price target of 11.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: NeurAxis, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.27.
Investor FAQ
Does NeurAxis, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is NeurAxis, Inc.?
NeurAxis, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -0.78.
Company Profile
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Community Discussion